By MEGHAN STANFIELD-BROWN The NHL will hold a news conference at 2:30 p.m.
ET to announce a new clinical trial that could one day provide a cure for prostate cancer.
The treatment will involve an injection of an experimental drug, which was approved by the U.S. Food and Drug Administration (FDA) on Monday.
The study will be conducted by the University of Southern California’s National Cancer Institute, which is one of the largest cancer centers in the world.
The FDA says it will begin a two-year clinical trial of the drug in men over age 65 who have undergone at least one cancer surgery, but not diagnosed with prostate cancer at the time.
The drug could be a breakthrough in the treatment of prostate cancer for men, which has become the second most common cause of death in men.
There are no studies to show whether it will reduce the risk of death, but the study could help doctors decide whether the treatment is right for a man’s particular type of cancer.
Researchers said the drug could help men live longer and reduce the chances of developing prostate cancer over time.
“We are very excited to be partnering with the USC National Cancer Institutes in this important trial,” Dr. John Bancroft, the head of the USC study, said in a statement.
“The goal of the clinical trial is to determine whether there is a difference between the dose and duration of therapy given in the current study and in another, similar study that we are conducting.”
The trial will be led by Dr. David Lipp, a leading oncologist at the University Medical Center in Munich, Germany, and Dr. Joseph Dolan, a professor of oncology at the UCLA School of Medicine.
The U.K.-based U.C.L.A. study was funded by the World Health Organization (WHO), the European Union, the European Commission and the U!
The U.N. agency will also contribute to the study.
The trial is expected to take about three years to complete, with results expected in 2021.
The results are expected to be presented in 2021, according to the National Cancer Council.
Dr. Dolan and other experts said the results could have significant implications for men in general and for men with advanced prostate cancer who may not yet have the benefit of treatment.
“I think it will have a very positive effect on patients,” Dr, John C. Bancrowt, professor of clinical oncologic sciences at the USC, said of the results.
The men in the USC trial will receive three different doses of the new drug — three different drug doses and three different dosage levels — for three years.
The new drug will be given as a single injection once a week and once every two weeks for up to 12 months.
Dr Bancroults trial will involve two different types of cancer treatments.
The first will be a “preliminary” trial, which will examine the efficacy of a single dose of the treatment for about 10 weeks.
The second will be longer-term, which would see the drug given in two separate injections for about six months.
The initial dose of drugs, known as the “posteriorly-active” drug, will be administered every two to three weeks for two to four weeks, then administered once every six to eight weeks.
The final dose will be used every four to six weeks, Dr Bancrts said.
“These are very important studies, which we hope to continue in the future,” Dr Bancaroft said.
The UCLA study will also include studies in mice, which are less aggressive than humans and can be administered a single treatment.
The drug was also tested on rats, which have similar characteristics to humans.
“It has been reported that a dose of parenteral (sic) therapy is effective in reducing prostate-specific antigen levels in mice,” Dr C.L., one of UCLA’s study lead authors, said.
“The purpose of this study is to confirm this finding and evaluate the safety and efficacy of pareto-therapy (sic), a therapy for prostate-cancer patients that involves the administration of a topical steroid and a gel.”